Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Moderate-to-Severe Atopic Dermatitis

Tundra lists 3 Moderate-to-Severe Atopic Dermatitis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT05590585

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health

Gender: All

Ages: 12 Years - Any

Updated: 2026-05-27

14 states

Moderate-to-Severe Atopic Dermatitis
Atopic Eczema
NOT YET RECRUITING

NCT07502222

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-03-30

Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING

NCT03989206

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Gender: All

Ages: 12 Years - Any

Updated: 2024-10-30

44 states

Moderate-to-Severe Atopic Dermatitis